Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Stock Information for Amarin Corporation plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Amarin Corporation plc

Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program
Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action 
Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering
Amarin Receives National Reimbursement for VAZKEPA® in Austria
Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025
Amarin Receives National Reimbursement for VAZKEPA® in Italy
Amarin Appoints Peter Fishman Chief Financial Officer
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.